Newer GLP-1RAs and GLP-1–based coagonists also appear promising and are being studied in separate trials for T2D, diabetic kidney disease, peripheral artery disease, and metabolic liver disease (Figure 1). This evidence concerns the gene GLP1R and diabetic kidney disease.